Company research
IRONWOOD PHARMACEUTICALS INC
CIK 1446847Updated Nov 20, 2026
IRWD price & chart
Loading TradingView…
NASDAQ:IRWD on TradingView ↗About the company
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G - filed by STATE STREET CORP regarding IRONWOOD PHARMACEUTICALS INC
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by BANK OF AMERICA CORP /DE/ regarding IRONWOOD PHARMACEUTICALS INC
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
4 filing
SCHEDULE 13G/A - filed by ARMISTICE CAPITAL, LLC regarding IRONWOOD PHARMACEUTICALS INC
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 396,062,000Source | 389,519,000Source | 285,128,000Source | 342,946,000Source | 395,620,000Source | 434,566,000Source | 327,213,000Source | 438,819,000Source | 396,901,000Source | 350,908,000Source | 471,073,000Source | 1,100,519,000Source |
| Property, Plant and Equipment, NetUSD | 3,666,000Source | 4,795,000Source | 2,913,000Source | 3,929,000Source | 5,068,000Source | 3,166,000Source | 4,256,000Source | 5,288,000Source | 3,408,000Source | 4,495,000Source | 5,585,000Source | 6,288,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 140,407,000Source | 88,211,000Source | 79,127,000Source | 92,852,000Source | 105,524,000Source | 220,471,000Source | 108,481,000Source | 121,540,000Source | 215,456,000Source | 88,559,000Source | 92,154,000Source | 656,203,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 120,370,000Source | 76,202,000Source | 112,732,000Source | 86,172,000Source | 58,108,000Source | 105,842,000Source | 39,768,000Source | 72,015,000Source | 46,745,000Source | 81,886,000Source | 129,122,000Source | 115,458,000Source |
| Assets, CurrentUSD | 273,843,000Source | 178,604,000Source | 199,201,000Source | 191,753,000Source | 178,180,000Source | 332,292,000Source | 160,579,000Source | 208,174,000Source | 274,178,000Source | 182,368,000Source | 233,288,000Source | 780,626,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,066,000Source | 14,191,000Source | 7,342,000Source | 12,729,000Source | 14,548,000Source | 5,979,000Source | 12,330,000Source | 14,619,000Source | 11,977,000Source | 11,923,000Source | 12,012,000Source | 7,715,000Source |
| Operating Lease, Right-of-Use AssetUSD | 9,775,000Source | 11,430,000Source | 8,443,000Source | 10,201,000Source | 11,823,000Source | 8,896,000Source | 10,619,000Source | 12,208,000Source | 9,340,000Source | 11,028,000Source | 12,586,000Source | 14,023,000Source |
| Other Assets, NoncurrentUSD | 4,844,000Source | 6,285,000Source | 3,874,000Source | 5,151,000Source | 4,257,000Source | 4,137,000Source | 5,538,000Source | 3,398,000Source | 4,502,000Source | 5,923,000Source | 3,608,000Source | 847,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 163,000Source | 160,000Source | 165,000Source | 162,000Source | 160,000Source | 165,000Source | 162,000Source | 159,000Source | 163,000Source | 160,000Source | 156,000Source | 154,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,671,442,000Source | -1,699,991,000Source | -1,581,654,000Source | -1,711,522,000Source | -1,703,637,000Source | -1,632,945,000Source | -1,735,121,000Source | -1,702,777,000Source | -1,673,718,000Source | -1,697,735,000Source | -1,698,615,000Source | -696,376,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,714,000Source | -2,052,000Source | -324,000Source | -2,026,000Source | -470,000Source | -795,000Source | 294,000Source | -922,000Source | -1,060,000Source | 923,000Source | -3,031,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | -264,157,000Source | -311,334,000Source | -161,843,000Source | -308,162,000Source | -321,727,000Source | -217,144,000Source | -334,053,000Source | -330,518,000Source | -261,835,000Source | -301,335,000Source | -346,295,000Source | 652,378,000Source |
| Additional Paid in Capital, Common StockUSD | 1,408,836,000Source | 1,390,549,000Source | 1,419,970,000Source | 1,405,224,000Source | 1,382,220,000Source | 1,416,431,000Source | 1,400,612,000Source | 1,373,022,000Source | 1,412,780,000Source | 1,395,317,000Source | 1,355,195,000Source | 1,348,600,000Source |
| Liabilities and EquityUSD | 396,062,000Source | 389,519,000Source | 285,128,000Source | 342,946,000Source | 395,620,000Source | 434,566,000Source | 327,213,000Source | 438,819,000Source | 396,901,000Source | 350,908,000Source | 471,073,000Source | 1,100,519,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 242,503,000Source | 49,383,000Source | 32,854,000Source | 232,525,000Source | 45,510,000Source | 236,307,000Source | 48,097,000Source | 252,442,000Source | 242,218,000Source | 38,846,000Source | 276,101,000Source | 25,525,000Source |
| Operating Lease, Liability, CurrentUSD | 3,236,000Source | 3,173,000Source | 3,285,000Source | 3,220,000Source | 3,157,000Source | 3,268,000Source | 3,204,000Source | 3,142,000Source | 3,252,000Source | 3,189,000Source | 3,126,000Source | 3,065,000Source |
| Accounts Payable, CurrentUSD | 1,613,000Source | 3,236,000Source | 911,000Source | 1,389,000Source | 3,227,000Source | 3,237,000Source | 5,827,000Source | 6,222,000Source | 2,898,000Source | 2,127,000Source | 7,830,000Source | 483,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,498,000Source | 12,882,000Source | 8,581,000Source | 11,117,000Source | 13,452,000Source | 9,233,000Source | 11,717,000Source | 14,004,000Source | 9,870,000Source | 12,304,000Source | 14,543,000Source | 16,599,000Source |
| Other Liabilities, NoncurrentUSD | 22,218,000Source | 39,771,000Source | 20,536,000Source | 22,466,000Source | 34,738,000Source | 21,170,000Source | 17,292,000Source | 29,414,000Source | 21,648,000Source | 17,105,000Source | 28,415,000Source | 9,766,000Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | 120,400,000Source | 76,200,000Source | 112,700,000Source | 86,200,000Source | 58,100,000Source | 105,800,000Source | 39,800,000Source | 72,000,000Source | 46,700,000Source | 81,900,000Source | 129,100,000Source | 130,000,000Source |
| Long-term DebtUSD | 199,506,000Source | 198,817,000Source | — | 199,332,000Source | 198,647,000Source | — | 199,160,000Source | 398,277,000Source | — | — | — | 396,251,000Source |
| Liabilities | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 40,080,000Source | 3,646,000Source | 51,291,000Source | 23,599,000Source | 40,773,000Source | -37,386,000Source | 24,017,000Source | 880,000Source | -1,031,559,000Source | 175,065,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 1,100,000Source | 1,200,000Source | 1,200,000Source | 1,400,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,653,000Source | 5,291,000Source | 17,250,000Source | 29,850,000Source | 32,005,000Source | 27,048,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 59,097,000Source | -42,118,000Source | -35,148,000Source | -47,236,000Source | -924,000Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 40,801,000Source | 68,051,000Source | 72,557,000Source | 65,739,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 5,121,000Source | 19,954,000Source | 127,044,000Source | 103,549,000Source | 183,427,000Source | 273,763,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -31,000Source | -34,000Source | -142,000Source | -1,026,318,000Source | -136,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 31,000Source | 34,000Source | 142,000Source | 273,000Source | 136,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | 737,000Source | — | — |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 126,394,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 6,000Source | 216,000Source | -106,970,000Source | 277,160,000Source | -237,553,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 5,015,000Source | 19,922,000Source | 126,897,000Source | -3,595,000Source | -565,784,000Source | 36,074,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 140,407,000Source | 88,211,000Source | 79,127,000Source | 92,852,000Source | 220,471,000Source | 108,481,000Source | 215,456,000Source | 88,559,000Source | 92,154,000Source | 657,938,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 30,333,000Source | 32,563,000Source | 13,552,000Source | 5,745,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 3,543,000Source | 8,408,000Source | 9,945,000Source | 4,615,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,612,000Source | 8,329,000Source | 3,236,000Source | 4,524,000Source | 3,653,000Source | 5,291,000Source | 17,250,000Source | 29,850,000Source | 59,553,000Source | 27,048,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 1,853,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | 1,904,000Source | 2,060,000Source | 1,853,000Source |
| DepreciationUSD | — | — | — | — | — | — | 443,000Source | 479,000Source | 1,881,000Source | 2,011,000Source | 1,575,000Source | 1,418,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | — | — | 19,000Source | 182,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -89,000Source | -75,000Source | — | -2,000Source |
| Income Tax Expense (Benefit)USD | — | — | 27,940,000Source | 13,723,000Source | 22,440,000Source | 14,223,000Source | 24,399,000Source | 1,114,000Source | 46,008,000Source | 64,318,000Source | 83,490,000Source | 77,357,000Source |
| InterestExpenseNonoperatingUSD | — | — | 8,434,000Source | 9,419,000Source | 7,203,000Source | 8,356,000Source | 9,141,000Source | 8,070,000Source | 32,746,000Source | 33,034,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 40,080,000Source | 3,646,000Source | 51,291,000Source | 23,599,000Source | 40,773,000Source | -37,386,000Source | 24,017,000Source | 880,000Source | -1,002,239,000Source | 175,065,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -29,320,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 40,080,000Source | 3,646,000Source | 51,291,000Source | 23,599,000Source | 40,773,000Source | -37,386,000Source | 24,017,000Source | 880,000Source | -1,002,239,000Source | 175,065,000Source |
| Nonoperating Income (Expense)USD | — | — | -7,464,000Source | -8,267,000Source | -5,576,000Source | -7,499,000Source | -7,401,000Source | -7,164,000Source | -28,477,000Source | -27,926,000Source | -2,639,000Source | 2,085,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 40,000Source | — | 42,000Source | 39,000Source | 42,000Source | 37,000Source | 193,000Source | 640,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 9,540,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 122,060,000Source | 91,592,000Source | 113,041,000Source | 85,239,000Source | 106,506,000Source | 41,143,000Source | 296,151,000Source | 351,410,000Source | 442,735,000Source | 410,596,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 21,908,000Source | 36,113,000Source | 11,313,000Source | 16,795,000Source | 12,033,000Source | 24,260,000Source | 82,256,000Source | 144,272,000Source | 158,314,000Source | 115,994,000Source |
| Operating Income (Loss)USD | — | — | 75,484,000Source | 25,636,000Source | 79,307,000Source | 45,321,000Source | 72,573,000Source | -29,108,000Source | 98,502,000Source | 93,124,000Source | -945,430,000Source | 250,337,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 40,000Source | — | 42,000Source | 39,000Source | 42,000Source | 37,000Source | 193,000Source | 640,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 68,020,000Source | 17,369,000Source | 73,731,000Source | 37,822,000Source | 65,172,000Source | -36,272,000Source | 70,025,000Source | 65,198,000Source | -948,069,000Source | 252,422,000Source |
| Income Tax Expense (Benefit)USD | — | — | 27,940,000Source | 13,723,000Source | 22,440,000Source | 14,223,000Source | 24,399,000Source | 1,114,000Source | 46,008,000Source | 64,318,000Source | 83,490,000Source | 77,357,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -29,320,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 40,080,000Source | 3,646,000Source | 51,291,000Source | 23,599,000Source | 40,773,000Source | -37,386,000Source | 24,017,000Source | 880,000Source | -1,002,239,000Source | 175,065,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.25Source | 0.02Source | 0.31Source | 0.15Source | 0.25Source | -0.23Source | 0.15Source | 0.01Source | -6.45Source | 1.13Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.23Source | 0.02Source | 0.31Source | 0.14Source | 0.24Source | -0.23Source | 0.15Source | 0.01Source | -6.45Source | 0.96Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 162,215,000Source | 159,706,000Source | 164,405,000Source | 161,723,000Source | 163,451,000Source | 160,974,000Source | 161,842,000Source | 159,083,000Source | 155,435,000Source | 154,366,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 177,764,000Source | 160,232,000Source | 167,179,000Source | 176,837,000Source | 166,690,000Source | 160,974,000Source | 162,983,000Source | 160,084,000Source | 155,435,000Source | 186,312,000Source |
| Interest Expense (non-operating)USD | — | — | 8,434,000Source | 9,419,000Source | 7,203,000Source | 8,356,000Source | 9,141,000Source | 8,070,000Source | 32,746,000Source | 33,034,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 46,576,000Source | 65,956,000Source | 33,734,000Source | 39,918,000Source | 33,933,000Source | 70,251,000Source | 197,649,000Source | 258,286,000Source | 1,388,165,000Source | 160,259,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 5,207,000Source | -3,733,000Source | 10,933,000Source | 11,618,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | — | — | 19,000Source | 182,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 161,155,000Source | 167,091,000Source | 226,532,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 21,629,000Source | 7,598,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 7,598,000Source |
| Investment Income, NetUSD | — | — | 930,000Source | 1,152,000Source | 1,585,000Source | 818,000Source | 1,698,000Source | 869,000Source | 4,076,000Source | 4,468,000Source | 18,971,000Source | 9,501,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 40,080,000Source | 3,646,000Source | 51,291,000Source | 23,599,000Source | 40,773,000Source | -37,386,000Source | 24,017,000Source | 880,000Source | -1,002,239,000Source | 175,065,000Source |
| Nonoperating Income (Expense)USD | — | — | -7,464,000Source | -8,267,000Source | -5,576,000Source | -7,499,000Source | -7,401,000Source | -7,164,000Source | -28,477,000Source | -27,926,000Source | -2,639,000Source | 2,085,000Source |
| Research and Development ExpenseUSD | — | — | 22,468,000Source | 29,827,000Source | 22,421,000Source | 23,373,000Source | 21,940,000Source | 27,432,000Source | 95,136,000Source | 111,421,000Source | 116,085,000Source | 44,265,000Source |
Filing attachments
tm2629044d1_ex99-1.htm · 8-K · 2026-11-05
Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance - Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.20 - $1.25 billion, representing greater than 35% increase year-over-year; Raises total 2026 revenue guidance to $485 - $510 million and adjusted EBITDA guidance to greater than $350 million - - Q3 2026 LINZESS U.S. net…
Read attachment ↗tm2627624d1_ex99-1.htm · 8-K · 2026-10-16
Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer - Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients - BOSTON, Mass., October 16, 2026 - Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare d…
Read attachment ↗tm2622244d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622244d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted EBITDA guidance to greater than $310 million - - Q2 2026 LINZESS U.S. net sales of $…
Read attachment ↗tm267094d1_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 tm267094d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results with 97% year-over-year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance - LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year - - Total revenue of $107 million, GAAP net income of $41 million and adjusted EBITDA of $77 mill…
Read attachment ↗tm267094d1_ex99-1.htm · 8-K · 2026-02-25
EX-99.1 2 tm267094d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE ───────────────── Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook - LINZESS ® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year - - 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million - - Continue to expect full-year 2026 LINZESS ®…
Read attachment ↗tm2534554d1_ex99-1.htm · 8-K · 2026-01-02
EX-99.1 2 tm2534554d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance - Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million - - Ended Q4 2025 with greater than $200 million in cash and cash equivalents - BOSTON, Mass., January 2, 2026 - Ironwood Pharmaceuticals, I…
Read attachment ↗